Publication

Discontinuation of antipsychotic medication-time to rethink trial design

Speyer, H., Begemann, M., Albert, N., Weller, A., Nordentoft, M., Veling, W., Sommer, I. E., Allott, K. & Killackey, E., Oct-2020, In : The Lancet. Psychiatry. 7, 10, p. 841-842 2 p.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

APA

Speyer, H., Begemann, M., Albert, N., Weller, A., Nordentoft, M., Veling, W., Sommer, I. E., Allott, K., & Killackey, E. (2020). Discontinuation of antipsychotic medication-time to rethink trial design. The Lancet. Psychiatry, 7(10), 841-842. https://doi.org/10.1016/S2215-0366(20)30340-0

Author

Speyer, Helene ; Begemann, Marieke ; Albert, Nikolai ; Weller, Amber ; Nordentoft, Merete ; Veling, Wim ; Sommer, Iris E ; Allott, Kelly ; Killackey, Eóin. / Discontinuation of antipsychotic medication-time to rethink trial design. In: The Lancet. Psychiatry. 2020 ; Vol. 7, No. 10. pp. 841-842.

Harvard

Speyer, H, Begemann, M, Albert, N, Weller, A, Nordentoft, M, Veling, W, Sommer, IE, Allott, K & Killackey, E 2020, 'Discontinuation of antipsychotic medication-time to rethink trial design', The Lancet. Psychiatry, vol. 7, no. 10, pp. 841-842. https://doi.org/10.1016/S2215-0366(20)30340-0

Standard

Discontinuation of antipsychotic medication-time to rethink trial design. / Speyer, Helene; Begemann, Marieke; Albert, Nikolai; Weller, Amber; Nordentoft, Merete; Veling, Wim; Sommer, Iris E; Allott, Kelly; Killackey, Eóin.

In: The Lancet. Psychiatry, Vol. 7, No. 10, 10.2020, p. 841-842.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Vancouver

Speyer H, Begemann M, Albert N, Weller A, Nordentoft M, Veling W et al. Discontinuation of antipsychotic medication-time to rethink trial design. The Lancet. Psychiatry. 2020 Oct;7(10):841-842. https://doi.org/10.1016/S2215-0366(20)30340-0


BibTeX

@article{8d5f8c1105a041caaffb533f8d080b8a,
title = "Discontinuation of antipsychotic medication-time to rethink trial design",
keywords = "Antipsychotic Agents/therapeutic use, Humans, Medication Adherence, Patient Dropouts, Patient Selection, Psychotic Disorders/drug therapy, Randomized Controlled Trials as Topic, Recurrence, Research Design",
author = "Helene Speyer and Marieke Begemann and Nikolai Albert and Amber Weller and Merete Nordentoft and Wim Veling and Sommer, {Iris E} and Kelly Allott and E{\'o}in Killackey",
year = "2020",
month = oct,
doi = "10.1016/S2215-0366(20)30340-0",
language = "English",
volume = "7",
pages = "841--842",
journal = "The Lancet. Psychiatry",
issn = "2215-0366",
publisher = "ELSEVIER SCI LTD",
number = "10",

}

RIS

TY - JOUR

T1 - Discontinuation of antipsychotic medication-time to rethink trial design

AU - Speyer, Helene

AU - Begemann, Marieke

AU - Albert, Nikolai

AU - Weller, Amber

AU - Nordentoft, Merete

AU - Veling, Wim

AU - Sommer, Iris E

AU - Allott, Kelly

AU - Killackey, Eóin

PY - 2020/10

Y1 - 2020/10

KW - Antipsychotic Agents/therapeutic use

KW - Humans

KW - Medication Adherence

KW - Patient Dropouts

KW - Patient Selection

KW - Psychotic Disorders/drug therapy

KW - Randomized Controlled Trials as Topic

KW - Recurrence

KW - Research Design

U2 - 10.1016/S2215-0366(20)30340-0

DO - 10.1016/S2215-0366(20)30340-0

M3 - Comment/Letter to the editor

C2 - 32949515

VL - 7

SP - 841

EP - 842

JO - The Lancet. Psychiatry

JF - The Lancet. Psychiatry

SN - 2215-0366

IS - 10

ER -

ID: 136300772